Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic
Study of the use of PVP-I gargles and nasal drops before ENT appointments finding good tolerability.
Khan et al., 18 Jun 2020, peer-reviewed, 3 authors.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
Am J Otolaryngol 41 (2020) 102618
Contents lists available at ScienceDirect
Am J Otolaryngol
journal homepage: www.elsevier.com/locate/amjoto
Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice
in Covid 19 pandemic
Mubarak Muhamed Khana, Sapna Ramkrishna Paraba, , Mandar Paranjapeb
Sushrut ENT Hospital and Dr. Khan's ENT Research Center, Talegaon Dabhade, India
Talegaon Dabhade, Pune, India
A R T I C LE I N FO
A B S T R A C T
SARS CoV 2
SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro
virucidal action of povidone iodine in SARS CoV and MERS. The oropharynx and nasopharynx are target sites of
SARS CoV 2. A signiﬁcant proportion of COVID 19 suﬀerers are asymptomatic, but shedding these viral particles,
PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries.
1. To propose the use of 0.5% Povidone iodine gargles and nasal drops as prerequisite for oﬃce based nose and
throat examination and procedures during COVID 19 pandemic.
2. To assess tolerability of 0.5% PVP-I in patients and in healthcare workers.
Materials and methods: 0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution.
Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for
30 s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior.
Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4%
xylocaine/adrenaline solution, tolerability and any allergic reaction noted.
Results: The patient and health care workers tolerated the 0.5%. No allergy was noted.
Conclusion: We propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of
spread of the disease in addition to the recommended PPE.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.